Trastuzumab.

Article Details

Citation
Copy to clipboard

Boekhout AH, Beijnen JH, Schellens JH

Trastuzumab.

Oncologist. 2011;16(6):800-10. doi: 10.1634/theoncologist.2010-0035. Epub 2011 May 31.

PubMed ID
21632460 [ View in PubMed
]
Abstract

Trastuzumab is standard of care in the treatment of human epidermal growth factor receptor (HER)-2(+) early and advanced breast cancer. Recently, it has been approved for the treatment of HER-2(+) advanced gastric cancer. Trastuzumab is an IgG1 humanized monoclonal antibody administered by intravenous infusion on a weekly or three weekly schedule. In all registered indications, trastuzumab is almost always given in combination with chemotherapy. In hormonal receptor-positive breast cancer in postmenopausal women, trastuzumab can be combined with an aromatase inhibitor. Main toxicity is reduction in the left ventricular ejection fraction, which in a minority of patients can become symptomatic, but in many patients is at least partly reversible. Long-term safety needs to be further determined.

DrugBank Data that Cites this Article

Drugs